Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010 (2010), Article ID 595934, 7 pages
http://dx.doi.org/10.1155/2010/595934
Review Article

Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents

1Interventional Cardiology Department, St. Ambrogio Clinical Institute, 20149, Milan, Italy
2Institute of Cardiology, Ospedale “Le Molinette”, University of Turin, 10124, Turin, Italy
3Department of Cardiology, Arcispedale S. Anna, University of Ferrara, 44100, Ferrara, Italy
4Department of Cardiology, Royal North Shore Hospital, North Shore Heart Research Group, Kolling Institute, University of Sydney, Sydney NSW 2065, Australia

Received 23 March 2010; Accepted 16 August 2010

Academic Editor: David Varon

Copyright © 2010 L. Testa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Kastrati, A. Schömig, and E. Schömig, “Are we making efficient use of clopidogrel?” European Heart Journal, vol. 25, no. 6, pp. 454–456, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Gent, “A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE),” Lancet, vol. 348, no. 9038, pp. 1329–1339, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Fox, M. A. Alonso Garcia, D. Ardissino et al., “Guidelines on the management of stable angina pectoris: executive summary—the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology,” European Heart Journal, vol. 27, no. 11, pp. 1341–1381, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. ACC/AHA, Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Developed in Collaboration With the Canadian Cardiovascular Society, 2008, http://www.cardiosource.com/.
  6. ACC/AHA, Guideline Update for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina), http://ww.cardiosource.com/.
  7. S. C. Smith Jr., T. E. Feldman, J. W. Hirshfeld Jr. et al., “ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention),” Catheterization and Cardiovascular Interventions, vol. 67, no. 1, pp. 87–112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. J. Angiolillo and F. Alfonso, “Clopidogrel-statin interaction: myth or reality?” Journal of the American College of Cardiology, vol. 50, no. 4, pp. 296–298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. O'Donoghue and S. D. Wiviott, “Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?” Circulation, vol. 114, no. 22, pp. e600–e606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Matetzky, B. Shenkman, V. Guetta et al., “Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction,” Circulation, vol. 109, no. 25, pp. 3171–3175, 2004. View at Google Scholar · View at Scopus
  11. K. P. Bliden, J. DiChiara, U. S. Tantry, A. K. Bassi, S. K. Chaganti, and P. A. Gurbel, “Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?” Journal of the American College of Cardiology, vol. 49, no. 6, pp. 657–666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Geisler, H. Langer, M. Wydymus et al., “Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation,” European Heart Journal, vol. 27, no. 20, pp. 2420–2425, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-P. Collet, J.-S. Hulot, A. Pena et al., “Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study,” The Lancet, vol. 373, no. 9660, pp. 309–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Simon, C. Verstuyft, M. Mary-Krause et al., “French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) investigators. Genetic determinants of response to clopidogrel and cardiovascular events,” The New England Journal of Medicine, vol. 360, no. 4, pp. 636–675, 2009. View at Google Scholar
  15. J. L. Mega, S. L. Close, S. D. Wiviott et al., “Cytochrome P-450 polymorphisms and response to clopidogrel,” New England Journal of Medicine, vol. 360, no. 4, pp. 354–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. D. Wiviott, E. Braunwald, C. H. McCabe et al., “Prasugrel versus clopidogrel in patients with acute coronary syndromes,” New England Journal of Medicine, vol. 357, no. 20, pp. 2001–2015, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Wallentin, R. C. Becker, A. Budaj et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes,” New England Journal of Medicine, vol. 361, no. 11, pp. 1045–1057, 2009. View at Publisher · View at Google Scholar
  18. D. L. Bhatt, A. M. Lincoff , C. M. Gibson et al., “CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI,” The New England Journal of Medicine, vol. 361, no. 24, pp. 2381–2329, 2009. View at Google Scholar
  19. R. A. Harrington, G. W. Stone, S. McNulty et al., “Platelet inhibition with cangrelor in patients undergoing PCI,” The New England Journal of Medicine, vol. 36, no. 24, pp. 2318–2329, 2009. View at Google Scholar
  20. L. Testa, R. Bhindi, W. J. van Gaal et al., “What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of Prasugrel,” International Journal of Medicine. In press.
  21. J. A. Jakubowski, K. J. Winters, H. Naganuma, and L. Wallentin, “Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile,” Cardiovascular Drug Reviews, vol. 25, no. 4, pp. 357–374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Hagihara, A. Kurihara, K. Kawai et al., “Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats,” Xenobiotica, vol. 37, no. 7, pp. 788–801, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. L. Smith, T. A. Gillespie, T. J. Rash, A. Kurihara, and N. A. Farid, “Disposition and metabolic fate of prasugrel in mice, rats, and dogs,” Xenobiotica, vol. 37, no. 8, pp. 884–901, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Niitsu, A. Sugidachi, T. Ogawa et al., “Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species,” European Journal of Pharmacology, vol. 579, no. 1–3, pp. 276–282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Sugidachi, F. Asai, K. Yoneda et al., “Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747,” British Journal of Pharmacology, vol. 132, no. 1, pp. 47–54, 2001. View at Google Scholar · View at Scopus
  26. A. L. Frelinger III, J. A. Jakubowski, Y. F. Li et al., “The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin,” Thrombosis and Haemostasis, vol. 98, no. 1, pp. 192–200, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. L. Frelinger, J. A. Jakubowski, Y. Li et al., “The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities,” Journal of Thrombosis and Haemostasis, vol. 6, no. 2, pp. 359–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Hasegawa, A. Sugidachi, T. Ogawa, T. Isobe, J. A. Jakubowski, and F. Asai, “Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor,” Thrombosis and Haemostasis, vol. 94, no. 3, pp. 593–598, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. J. J. Van Giezen and R. G. Humphries, “Preclinical and clinical studies with selective reversible direct P2Y 12 antagonists,” Seminars in Thrombosis and Hemostasis, vol. 31, no. 2, pp. 195–204, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. U. S. Tantry, K. P. Bliden, and P. A. Gurbel, “AZD6140,” Expert Opinion on Investigational Drugs, vol. 16, no. 2, pp. 225–229, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. Nassim, J. B. Sanderson, C. Clarke et al., “Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers,” Journal of the American College of Cardiology, vol. 33, no. 2, supplement A, p. 255A, 1999. View at Google Scholar
  32. A. H. Ingall, J. Dixon, A. Bailey et al., “Antagonists of the platelet P(2T) receptor: A novel approach to antithrombotic therapy,” Journal of Medicinal Chemistry, vol. 42, no. 2, pp. 213–220, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Wallentin, C. Varenhorst, S. James et al., “Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease,” European Heart Journal, vol. 29, no. 1, pp. 21–30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. D. Wiviott, D. Trenk, A. L. Frelinger et al., “PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial,” Circulation, vol. 116, pp. 2923–2932, 2007. View at Google Scholar
  35. S. D. Wiviott, E. M. Antman, K. J. Winters et al., “Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial,” Circulation, vol. 111, no. 25, pp. 3366–3373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. V. L. Serebruany, M. G. Midei, H. Meilman, A. I. Malinin, and D. R. Lowry, “Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: The subset from the JUMBO study,” Postgraduate Medical Journal, vol. 82, no. 968, pp. 404–410, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. D. Wiviott, E. Braunwald, and C. H. McCabe, “TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 357, pp. 2001–2015, 2007. View at Google Scholar
  38. S. D. Wiviott, E. Braunwald, C. H. McCabe et al., “Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial,” The Lancet, vol. 371, no. 9621, pp. 1353–1363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. E. M. Antman, S. D. Wiviott, S. A. Murphy et al., “Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention. A TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibitioN with prasugrel-thrombolysis in myocardial infarction) analysis,” Journal of the American College of Cardiology, vol. 51, no. 21, pp. 2028–2033, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. D. Wiviott, E. Braunwald, D. J. Angiolillo et al., “TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38,” Circulation. In press.
  41. G. Montalescot, S. D. Wiviott, E. Braunwald et al., “Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial,” The Lancet, vol. 373, no. 9665, pp. 723–731, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. L. Mega, S. L. Close, S. D. Wiviott et al., “Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes,” Circulation, vol. 119, no. 19, pp. 2553–2560, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. C. P. Cannon, S. Husted, R. A. Harrington et al., “Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome. primary results of the DISPERSE-2 trial,” Journal of the American College of Cardiology, vol. 50, no. 19, pp. 1844–1851, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Subherwal, R. G. Bach, and A. Y. Chen, “The CRUSADE bleeding score to assess baseline risk of major bleeding in non-ST-segment elevation myocardial infarction,” Journal of American College of Cardiology, vol. 51, supplement A, pp. 806–809, 2008. View at Google Scholar
  45. M. Moscucci, K. A. A. Fox, C. P. Cannon et al., “Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE),” European Heart Journal, vol. 24, no. 20, pp. 1815–1823, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Nikolsky, R. Mehran, G. Dangas et al., “Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach,” European Heart Journal, vol. 28, no. 16, pp. 1936–1945, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. K. Mehta, A. D. Frutkin, J. B. Lindsey et al., “Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the national cardiovascular data registry,” Circulation: Cardiovascular Interventions, vol. 2, no. 3, pp. 222–229, 2009. View at Publisher · View at Google Scholar
  48. G. Biondi Zoccai, M. Lotrionte, A. Abbate et al., “Is prasugrel superior to ticagrelor For the treatment of patients with acute coronary syndromes? evidence from a 32,893-patient adjusted indirect comparison meta-analysis,” in Proceedings of the Cardiovascular Revascularization Therapy Conference, Washington, DC, USA, February 2010.